1 active not recruiting, 1 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Noonan Syndrome 5: new trials by email Literature Review of Noonan Syndrome 5 trials Research Report on Noonan Syndrome 5
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Tovorafenib, Chemotherapeutic Agent - Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma | Phase 3 | Active not recruiting | Day One Biopharmaceuticals, Inc. | 418 | 2023-02-27 | 2026-10-19 |
| MEK162 for Patients With RAS/RAF/MEK Activated Tumors MEK162 - Solid Tumor and Hematologic Malignancies | Phase 2 | Completed | Pfizer | 110 | 2013-10-10 | 2021-02-21 |
Carcinoma, Non-Small-Cell Lung (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Antineoplastic Agents (1) · Carboplatin (1) · binimetinib (1) · tovorafenib (1)
Day One Biopharmaceuticals, Inc. (1) · Pfizer (1)
United States (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Egypt (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Ireland (1)